GlassScriptPhysician profile
Debra Pruzan
NPI 1679575112
$4,354.14
in general payments reported to CMS, 2019-2025
27 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $188 · 2022: $210 · 2023: $942 · 2024: $1,198 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $959.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $454.00 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $366.54 | 2023-2025 | Tremfya, Remicade, Stelara |
| Incyte Corporation | $346.62 | 2023-2025 | Opzelura |
| Genzyme Corporation | $332.09 | 2019-2025 | |
| Pfizer INC. | $313.08 | 2019-2025 | |
| Leo Pharma INC. | $208.93 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $201.25 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Mayne Pharma Commercial LLC | $163.45 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $142.68 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.13 | 2019-2025 | Cabtreo |
| Arcutis Biotherapeutics, INC. | $119.89 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $102.10 | 2019-2024 | Odomzo, Blu-U |
| Galderma Laboratories, L.P. | $100.73 | 2019-2025 | Nemluvio |
| Almirall LLC | $69.77 | 2019-2025 | Klisyri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $65.22 | 2019-2022 | |
| Amgen INC. | $53.57 | 2019-2025 | Otezla |
| Dermavant Sciences, INC. | $50.26 | 2023-2024 | Vtama |
| Mission Pharmacal Company | $31.85 | 2019-2020 | |
| Biofrontera INC. | $24.43 | 2022 | |
| Botanix Sb INC | $24.02 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $18.48 | 2023 | Ycanth |
| Solta Medical, A Division of Bausch Health US, LLC | $18.30 | 2023 | |
| Sebela Pharmaceuticals INC. | $16.86 | 2023 | Pramosone, Naftin |
| Celgene Corporation | $16.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.20 | 2025 | Sotyktu |
| Prugen, INC. Pharmaceuticals | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Pruzan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.